These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 28923212)
1. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Fessas P; Lee H; Ikemizu S; Janowitz T Semin Oncol; 2017 Apr; 44(2):136-140. PubMed ID: 28923212 [TBL] [Abstract][Full Text] [Related]
2. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Tan S; Zhang H; Chai Y; Song H; Tong Z; Wang Q; Qi J; Wong G; Zhu X; Liu WJ; Gao S; Wang Z; Shi Y; Yang F; Gao GF; Yan J Nat Commun; 2017 Feb; 8():14369. PubMed ID: 28165004 [TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma. Ivashko IN; Kolesar JM Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495 [TBL] [Abstract][Full Text] [Related]
4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
6. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415 [TBL] [Abstract][Full Text] [Related]
7. Safety of pembrolizumab for the treatment of melanoma. Martin-Liberal J; Kordbacheh T; Larkin J Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979 [TBL] [Abstract][Full Text] [Related]
8. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. Weber JS; Postow M; Lao CD; Schadendorf D Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894 [TBL] [Abstract][Full Text] [Related]
9. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy. Issafras H; Fan S; Tseng CL; Cheng Y; Lin P; Xiao L; Huang YJ; Tu CH; Hsiao YC; Li M; Chen YH; Ho CH; Li O; Wang Y; Chen S; Ji Z; Zhang E; Mao YT; Liu E; Yang S; Jiang W PLoS One; 2021; 16(12):e0257972. PubMed ID: 34972111 [TBL] [Abstract][Full Text] [Related]
10. Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system. Nastoupil LJ; Neelapu SS Curr Oncol Rep; 2015 Jul; 17(7):30. PubMed ID: 25986722 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry. Tavares ABMLA; Lima Neto JX; Fulco UL; Albuquerque EL Sci Rep; 2018 Jan; 8(1):1840. PubMed ID: 29382901 [TBL] [Abstract][Full Text] [Related]
12. Biophysical and Immunological Characterization and Hutchins B; Starling GC; McCoy MA; Herzyk D; Poulet FM; Dulos J; Liu L; Kang SP; Fayadat-Dilman L; Hsieh M; Andrews CL; Ayanoglu G; Cullen C; Malefyt RW; Kastelein RA; Saux SL; Lee J; Li S; Malashock D; Sadekova S; Soder G; van Eenennaam H; Willingham A; Yu Y; Streuli M; Carven GJ; van Elsas A Mol Cancer Ther; 2020 Jun; 19(6):1298-1307. PubMed ID: 32229606 [TBL] [Abstract][Full Text] [Related]
13. Programmed cell death ligand-1: A dynamic immune checkpoint in cancer therapy. Kalim M; Iqbal Khan MS; Zhan J Chem Biol Drug Des; 2020 Jun; 95(6):552-566. PubMed ID: 32166894 [TBL] [Abstract][Full Text] [Related]
15. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Lee JY; Lee HT; Shin W; Chae J; Choi J; Kim SH; Lim H; Won Heo T; Park KY; Lee YJ; Ryu SE; Son JY; Lee JU; Heo YS Nat Commun; 2016 Oct; 7():13354. PubMed ID: 27796306 [TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. Almutairi AR; Alkhatib N; Martin J; Babiker HM; Garland LL; McBride A; Abraham I Crit Rev Oncol Hematol; 2019 Oct; 142():16-25. PubMed ID: 31326706 [TBL] [Abstract][Full Text] [Related]